Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab
Primary Purpose
Hypertension
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Nebivolol
Lisinopril
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension as a result of bevacizumab therapy
Eligibility Criteria
Inclusion Criteria:
- Patients currently treated at the University of Mississippi Medical Center Oncology Clinic
- Patient is being treated with bevacizumab either alone or in combination with other agents for cancer
- Patient blood pressure is >140 mmHg (systolic) or > 90 mmHg (diastolic), either treated or untreated with medications for hypertension
- Patients may be currently on medications for hypertension (other than Beta blocker, ACEI, or ARB); these will be continued at the same dose throughout the study
- Patients should be > 18 years of age
- Patients receiving bevacizumab therapy approximately every 2 weeks
Exclusion Criteria:
- History of ACEI or ARB induced angioedema or idiopathic/hereditary angioedema
- Patient currently treated with a Beta blocker, ACEI, or ARB or have a history of intolerance to a medication in any of these classes
- Hyperkalemia, defined as a potassium value of >5 mEq/L
- Pregnancy or breastfeeding
- Severe renal impairment (eGFR <30 mL/min)
- Moderate hepatic impairment as identified by physician
- Currently taking CYP2D6 inducers (rifampin, carbamazepine or dexamethasone) or inhibitors (bupropion, fluoxetine, paroxetine, duloxetine, etc.)
- History of clinically significant EKG abnormality which would contraindicate beta blocker use
- Recent stroke (<6 months)
- Recent myocardial infarction (<6 months)
- Congestive heart failure
- Severe asthma or COPD
- Diagnosed obstructive sleep apnea
Sites / Locations
- University of Mississippi Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Nebivolol
Lisinopril
Arm Description
Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
Outcomes
Primary Outcome Measures
The primary endpoint of the study will be changes in sitting systolic and diastolic blood pressure at the crossover and final visits.
Patients will be treated with both nebivolol or lisinopril for a period of 4 weeks, and then crossover to the opposite medication for an additional 4 weeks.
Secondary Outcome Measures
The secondary endpoint of the study will be changes in heart rate at the end of the crossover and final visits.
Patients will be treated with both nebivolol or lisinopril for a period of 4 weeks, and then crossover to the opposite medication for an additional 4 weeks.
Full Information
NCT ID
NCT01076140
First Posted
February 24, 2010
Last Updated
April 5, 2012
Sponsor
University of Mississippi Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01076140
Brief Title
Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab
Official Title
Comparative Blood Pressure Effects of Nebivolol Versus Lisinopril in Patients With New Onset or Exacerbated Hypertension Induced by Bevacizumab: a Crossover Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2012
Overall Recruitment Status
Withdrawn
Why Stopped
No participants enrolled
Study Start Date
February 2010 (undefined)
Primary Completion Date
January 2011 (Anticipated)
Study Completion Date
August 2011 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Mississippi Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to directly compare the blood pressure (hypertension) reduction effects of lisinopril and nebivolol in patients who develop new onset or worsening hypertension while treated with bevacizumab.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension as a result of bevacizumab therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nebivolol
Arm Type
Active Comparator
Arm Description
Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
Arm Title
Lisinopril
Arm Type
Active Comparator
Arm Description
20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Intervention Description
Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
Intervention Type
Drug
Intervention Name(s)
Lisinopril
Intervention Description
Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
Primary Outcome Measure Information:
Title
The primary endpoint of the study will be changes in sitting systolic and diastolic blood pressure at the crossover and final visits.
Description
Patients will be treated with both nebivolol or lisinopril for a period of 4 weeks, and then crossover to the opposite medication for an additional 4 weeks.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
The secondary endpoint of the study will be changes in heart rate at the end of the crossover and final visits.
Description
Patients will be treated with both nebivolol or lisinopril for a period of 4 weeks, and then crossover to the opposite medication for an additional 4 weeks.
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients currently treated at the University of Mississippi Medical Center Oncology Clinic
Patient is being treated with bevacizumab either alone or in combination with other agents for cancer
Patient blood pressure is >140 mmHg (systolic) or > 90 mmHg (diastolic), either treated or untreated with medications for hypertension
Patients may be currently on medications for hypertension (other than Beta blocker, ACEI, or ARB); these will be continued at the same dose throughout the study
Patients should be > 18 years of age
Patients receiving bevacizumab therapy approximately every 2 weeks
Exclusion Criteria:
History of ACEI or ARB induced angioedema or idiopathic/hereditary angioedema
Patient currently treated with a Beta blocker, ACEI, or ARB or have a history of intolerance to a medication in any of these classes
Hyperkalemia, defined as a potassium value of >5 mEq/L
Pregnancy or breastfeeding
Severe renal impairment (eGFR <30 mL/min)
Moderate hepatic impairment as identified by physician
Currently taking CYP2D6 inducers (rifampin, carbamazepine or dexamethasone) or inhibitors (bupropion, fluoxetine, paroxetine, duloxetine, etc.)
History of clinically significant EKG abnormality which would contraindicate beta blocker use
Recent stroke (<6 months)
Recent myocardial infarction (<6 months)
Congestive heart failure
Severe asthma or COPD
Diagnosed obstructive sleep apnea
Facility Information:
Facility Name
University of Mississippi Medical Center
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab
We'll reach out to this number within 24 hrs